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Abstract
Over 100 associated genetic loci have been robustly associated with schizophrenia. Gene prioritization and pathway analysis
have focused on a priori hypotheses and thus may have been unduly influenced by prior assumptions and missed important
causal genes and pathways. Using a data-driven approach, we show that genes in associated loci: (1) are highly expressed in
cortical brain areas; (2) are enriched for ion channel pathways (false discovery rates <0.05); and (3) contain 62 genes that are
functionally related to each other and hence represent promising candidates for experimental follow up. We validate the
relevance of the prioritized genes by showing that they are enriched for rare disruptive variants and de novo variants from
schizophrenia sequencing studies (odds ratio 1.67, P = 0.039), and are enriched for genes encoding members of mouse and
human postsynaptic density proteomes (odds ratio 4.56, P = 5.00 × 10−4; odds ratio 2.60, P = 0.049).The authors wish it to be
known that, in their opinion, the first 2 authors should be regarded as joint First Author.
Received: August 17, 2015. Revised: December 29, 2015. Accepted: January 5, 2015
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com
Human Molecular Genetics, 2016, Vol. 25, No. 6 1247–1254
doi: 10.1093/hmg/ddw007
Advance Access Publication Date: 10 January 2016
Association Studies Article
1247
Introduction
Despite recent successes in identifying rare and common genetic
variants that associate with schizophrenia, the etiology of the
disorder still remains unclear (1). Large-scale studies of de novo
variants, rare variants and common variants have implicated
the postsynaptic density (PSD) (2–4), calcium channels (4–6), tar-
gets of the fragile X mental retardation protein (FMRP, product of
FMR1) (3,4,7), targets of micro-RNA mir-137 (8), glutamate path-
ways (9), and processes related to neurogenesis and synaptic in-
tegrity (7,9–11). However, our knowledge of the genes involved in
the etiology of schizophrenia is far from complete, and in many
instances, the evidence implicating putative pathogenic path-
ways is not decisive.
We and others have recently shown that well-powered
genome-wide association studies (GWAS) of complex traits, com-
bined with data-driven, mechanism-agnostic pathway analyses,
enable identification of likely causal genes and pathways and
thus provide a solid foundation for understanding causal biology
(12–16). In schizophrenia, common variants are estimated to
account for at least a third of genetic risk (5,17) and recent
GWAS has identified more than 100 robustly associated loci (6).
Compared to GWAS-based pathway analysis of anthropomet-
ric traits, efforts to prioritize likely causal genes and enriched
pathways for schizophrenia have until recently been limited by
the lack of genome-wide significant associations and incomplete
defined pathways (18). Moreover, except for a few studies (19–23),
these analyses have been limited to either preselected pathways
with a priori evidence for schizophrenia or have only identified
pathways that are shared across psychiatric disorders (Supple-
mentary Material, see (18) for a review). Furthermore, few of
these analyses are followed up with independent validation.
Consequently, there is a need for a comprehensive gene priori-
tization and pathway analysis approach for schizophrenia that
includes unbiased validation and does not rely on pre-specified
hypotheses.
Spatial and temporal expression patterns of implicated genes
are also important to identifying promising drug targets and un-
derstanding etiology. Results from previous exome sequencing
studies of de novo mutations in schizophrenia have suggested
that likely causal schizophrenia genes are highly expressed
during fetal development (10,11,24), but failed to replicate in the
to-date largest schizophrenia exome sequencing study (3). Conse-
quently furtherwork is needed to investigatewhether likely causal
schizophrenia genes have a prenatal or postnatal expression bias.
To obtain a more comprehensive portrait of likely causal
genes and biological pathways underlying schizophrenia, we ap-
plied our framework (25) for interpretation of genetic association
studies (called DEPICT) to 128 genome-wide significant associa-
tions with schizophrenia recently reported by the Psychiatric
Genomics Consortium (PGC) (6). DEPICT uses improved biological
pathwayand gene set definitions (henceforth ‘reconstituted gene
sets’) to systematically prioritize the most likely causal gene(s) at
associated GWAS loci and to assess whether genes in associated
GWAS loci enrich for reconstituted gene sets and/or are highly ex-
pressed in specific tissues, brain areas or cell types (25). The use of
reconstituted gene sets to prioritize genes and pathways is a key
difference between DEPICT and other pathway methods (25) and
DEPICT has been successfully applied to awide range of polygen-
ic traits (13,14,16,26,27). We validated the prioritized schizophre-
nia genes using previously published exome sequencing data
(3,4) and postsynaptic density proteomics data (2). Finally, we
show that prioritized genes tend to be higher expressed post-
natally than prenatally.
Results
To decipher the biology implicated by GWAS loci associated with
schizophrenia, we applied DEPICT to genome-wide significant
associations (P < 5 × 10−8) recently identified by the PGC (6).
Using 123 autosomal, non-human leukocyte antigen associated
SNPs as the input to DEPICT, we first generated 109 independent
loci (this differs slightly from the PGCwhich used a different pro-
cedure to define associated loci). We first tested whether genes in
these associated loci displayed higher expression levels in par-
ticular tissues and brain areas than genes outside associated
loci using RNA sequencing (RNA-Seq) data from 37 tissues evalu-
ated in the Genotype-Tissue Expression Project (GTEx) (28). We
identified five significant tissues (false discovery rates, FDR < 5%),
all representing areas in the brain: cortex, frontal cortex (BA9),
anterior cingulate cortex (BA24), nucleus accumbens, caudate
(Fig. 1; Supplementary Material, Table S2). These findings are
consistent with previous data showing that schizophrenia-asso-
ciated variants co-localize with genes highly expressed in the
brain (6,10,11,24) and in particular structures in the cortex (11).
Having confirmed that genes within genome-wide significant
schizophrenia loci arehighly expressed in the brain, wenext used
DEPICT to systematically assess for enrichment of reconstituted
gene sets representing a wide range of biological pathways, mo-
lecular processes, cellular compartments/structures, protein
complexes andmouse phenotypes.We identified 104 significant-
ly enriched reconstituted gene sets (FDR < 0.05, Supplementary
Material, Fig. S1 and Table S3), comprising 15 canonical pathways
(29,30) including ion channels, glutamate, serotonin/dopamine
and neuronal growth factor signaling (P = 8.08 × 10−5) and long
term potentiation (P < 6.44 × 10−4; Table 1); and 89 additional
gene sets representingmolecular function and biological process
Gene Ontology terms (31), morphological and physiological
mouse phenotypes (32) and protein complexes (33).
We considered that this analysis could simply highlight generic
pathways enriched in genes expressed in the brain. To assess this
possibility, we tested whether the gene sets highlighted by DEPICT
from the schizophrenia-associated loci differed from gene sets en-
riched in analyses based on randomly selected ‘brain loci,’ each
containing a gene highly expressed in the brain (see Methods).
We ran DEPICT on 100 such control sets of randomly selected
brain loci and found that 20 out of the 104 gene sets remained sig-
nificantly enriched when compared with these 100 control ana-
lyses (empirical P < 0.05). These gene sets clustered in five groups
related to ‘channel activity’, ‘central nervous system projection
neuron axonogenesis’, the ‘HOMER1 protein complex’ (HOMER1
constitutes a major part of the postsynaptic density), ‘cell rec-
ognition’, and ‘phosphatidylinositol signaling system’ (all
with P < 6.2 × 10−4; Supplementary Material, Table S4).
Finally, to directly test for enrichment of gene sets that were
implicated in recent exome sequencing studies (3,4), namely tar-
gets of the FMRP (34), glutamatergic postsynaptic proteins com-
prising activity-regulated cytoskeleton-associated protein
(ARC), and N-methyl-D-aspartate receptor (NMDAR) complexes,
we reconstituted these gene sets and computed their enrichment
(see Methods). The only enriched reconstituted gene set was tar-
gets of FMRP (P = 4.16 × 10−6). Furthermore, to assesswhether pro-
cesses active in the pre-synapse and synaptic vesicles also were
enriched in the genome-wide significant loci, we reconstituted
gene sets encoding proteins isolated in proteomics experiments
of rodent pre-synaptic active zones (35,36), pre-synaptic docking
complexes (37), and synaptic vesicles (38). However, none of
these four gene sets were significantly enriched (Supplementary
Material, Table S5). Jointly, these results implicate processes
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related to dendritic spines, synaptic plasticity, and cognition/ab-
normal behavior but do not support key roles of presynaptic pro-
cesses, the immune system or histone-related processes.
To identify likely casual schizophrenia genes, we used DEPICT
to prioritize genes within the genome-wide significant loci, the
majority of which contained more than one gene. In DEPICT, a
gene within an associated locus is prioritized if it exhibits higher
than expected pairwise similarities to genes fromother associated
loci (across 14,461 functional predictions). DEPICT prioritized 62
genes at 51 genome-wide significant loci (Supplementary Mater-
ial, Table S6), including genes that have not been specifically
hypothesized for schizophrenia before (e.g. PITPNM2, prioritiza-
tion P = 4.13 × 10−8; DGKI, prioritization P = 1.03 × 10−7 and DGKZ,
prioritization P = 4.95 × 10−6). Tovalidate the relevanceof the prior-
itized genes,weused previously published exome sequencing and
PSD proteomics data that were not part of the DEPICT framework
to compute the following four benchmarks. We then tested
whether genes prioritized by DEPICT were more likely to harbor
rare (MAF < 0.1%) disruptive variants (nonsense, essential splice
site and frameshiftmutations) in exome sequences of schizophre-
nia cases compared to controls, and whether prioritized genes
weremore likely thannon-prioritized genes to contain de novomu-
tations in schizophrenia probands (3). Our results suggest that the
prioritized genes enrich for these two previously identified groups
of likely schizophrenia genes (odds ratio, OR, 1.67; one-sidedCoch-
ran Mantel-Haenszel statistic test P = 0.039; See Methods and
Supplementary Material, Table S7). Finally, we tested whether
prioritized genes are enriched for genes encoding members of
either human or mouse cortex PSD proteomes (39). Prioritized
genes strongly enriched for gene products from the human PSD (OR
2.60, one-sided P=0.049) andmouse PSD (OR 4.56, one-sided P=5.00
×10−4) when compared to non-prioritized genes at associated loci.
Among the prioritized genes were two genes, GRIN2A and
RIMS1, that exhibited a surplus of disruptive variants in schizo-
phrenic cases compared to controls (4), de novo variants (3), and
encoded members of the PSD. However, DEPICT also prioritized
14 genes with a surplus of disruptive variants or a de novo variant
that did not encode PSD members (see Supplementary Material,
Table S8). Predicted functions of these genes were related to
diacylglycerol kinase activity (PITPNM2), hormone levels
(KIAA1324L, GRAMD1B), neurotransmitter signaling (HCN1,
CSMD1, KCNV1, SLC45A1, PCDHAC2), hippocampal pyramidal cell
morphology and GTPase binding/activation (AKT3, PPP1R13B), ion
channels (CNTN4, MBD5) and the innate immune system
(CALHM2, PLCB2). Finally, DEPICT-prioritized genes included DRD2,
whichencodes themain target of effective antipsychotic drugs (pri-
oritization P = 0.002), although this gene was not present in any of
the four benchmark lists. Thus, while the sequencing and proteo-
mics data provide validation of the prioritization by DEPICT, they
are also clearly incomplete and imperfect benchmarks.
Having shown that prioritized genes enrich for rare variants
in relevant exome sequencing studies and encode proteins that
co-localize in the human and mouse PSDs, we investigated
their temporal expression pattern using RNA-Seq-based post-
mortem brain expression data from the BrainSpan database
(40), which covers stages from early prenatal developmental
through infancy, adolescence and adulthood. In contrast to the
previous studies reporting higher expression of likely causal
schizophrenia genes during prenatal development (10,11,24),
we observed higher expression levels in the postnatal period
(fold-change 1.29; one-sided paired t-test P = 0.005; Fig. 2 and Sup-
plementary Material, Fig. S2). We replicated these results using
BrainSpan Developmental Transcriptome microarray-based
gene expression data (fold-change 1.06, one-sided paired t-test
P = 0.002; Supplementary Material, Fig. S3). We performed nega-
tive control analyses and found that methodological biases
were unlikely to explain the tendency toward increased postnatal
expression of prioritized genes (Supplementary Note). Together
these results demonstrate that likely schizophrenia genes impli-
cated by GWAS studies may act later in the life course.
Discussion
Recent genome-scale studies have substantially advanced our
understanding of schizophrenia (3,4,6,9–11). Here, we used previ-
ously published schizophrenia GWAS data in conjunction with a
data-driven integrative approach to prioritize 62 genes and 104
reconstituted gene sets for schizophrenia. Our work differs
Figure 1. Genes in genome-wide significant schizophreniameta-analysis loci enrich for cortical structures of the brain.We used DEPICT and RNA-Seq data from the GTEx
Project to assess whether genes in genome-wide significant schizophrenia loci were highly expressed in any of 37 tissue/brain area annotations. Genes within the
associated loci were highly expressed in 5 brain areas, most predominantly in the frontal cortex. Enrichments are grouped according to tissue-type annotations and
significance, and annotations colored in black exhibited false discovery rates below 5%.
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from previous pathway analyses in an important respect: it is not
based on a priori selection of candidate genes and gene sets
but rather treats each gene set and the genes in associated loci
equally. As a result, this work has the potential to validate the
importance of previous hypotheses and also to prioritize as yet
unidentified biological processes/structures, protein complexes,
mouse phenotypes and genes. Importantly, we validate the rele-
vance of the genes prioritized using our approach by replicating
them using exome sequencing data and PSD proteomics data.
Our work has several main findings. Using strict significance
criteria, we implicate numerous gene sets and genes; in particu-
lar, we show that genes in associated schizophrenia loci enrich
for reconstituted gene sets related to biological processes and
mouse phenotypes including dendritic spine development, cal-
cium, glutamate and neuronal growth factor signaling, and syn-
aptic transmission, but also less well-established processes such
as diacylglycerol kinase activity (DGKI,DGKZ, and PITPNM2). Thus
ourwork provides further evidence for the importance of the PSD
and dendritic spines in schizophrenia (41). Four of the top five
most enriched gene sets nominally significant in (22) are signifi-
cant in our work (postsynaptic density, postsynaptic membrane,
dendritic spine, axon part). However, we did not find any support
for gene sets related to histone H3-K4 methylation, nor do our
analyses, unlike previous epidemiological (42) and genetic (6,22)
studies, support a link between the immune system and schizo-
phrenia. We note that the HLA locus is strongly associated with
schizophrenia (6). Many immune-related genes reside in the
large regions of linkage disequilibriumwithinHLA, so strong gen-
etic associations in this region often lead pathway-based meth-
ods to spuriously implicate immune-related pathways; for this
reason, DEPICT omits the HLA locus from analysis.
Genes expressed during adolescence and adulthood, the ages
at which schizophrenia is typically diagnosed, might represent
more appealing drug targets than developmental genes that act
prenatally. We show that likely causal genes in schizophrenia
GWAS loci exhibit higher expression during postnatal stages
compared to prenatal stages. Similarly, Purcell et al. (4) showed
that schizophrenia genes selected based on a broad basis of
prior evidence for schizophrenia, exhibit postnatal- rather than
prenatal bias in their expression (in the hippocampus and dorso-
lateral prefrontal cortex) (4). Moreover, using BrainSpan micro-
array expression data, the PGC recently showed that expression
of genes encoding members of immunological and neuronal
pathways jointly associated with schizophrenia, major depres-
sion and bipolar disorder, increased during childhood and plat-
eaued around adolescence (22). These and our findings contrast
previous studies reporting genes with higher expression in pre-
natal developmental stages (10,11,24).
A benchmark is only as good as the data used to evaluate it.
Schizophrenia sequencing studies are still underpowered to
identify susceptibility genes and it is likely that additional etio-
logic biological processes and structures besides the PSD will
emerge (43). DEPICT prioritized several genes outside the PSD
(e.g. DGKI, NRGN, CACNA1I, and DRD2), which are not included
in any of the benchmarks used in this work, but are nevertheless
strong candidates for causal contributors to schizophrenia. Fu-
ture genetic studies will provide more complete data sets with
which to benchmark prioritization methods and to identify add-
itional causal genes and biological mechanisms.
In summary, by taking a data-driven approach that is not
biased toward preformed hypotheses about the etiology of
schizophrenia, and applying this approach to large-scale schizo-
phrenia GWAS data, we have prioritized genes and gene sets as
potentially causal for schizophrenia. We show that prioritizedT
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genes are enriched for disruptive variants in schizophrenia cases,
often encode proteins localized in the PSD and are more likely to
be expressed postnatally. Our work provides an example of com-
bining large-scale neurogenetics data with data-driven method-
ologies to understand biological processes underlying
neuropsychiatric traits.
Materials and Methods
Genome-wide association study data for schizophrenia
Genome-wide significant association (P < 5 × 10−8) from the PGC
schizophrenia GWAS (6) were used as input for DEPICT. We omit-
ted three X chromosome SNPs, one human leukocyte antigen
SNP (rs115329265), and variant chr10_104957618 (which could
not be mapped, but was covered by rs12887734) and used the
resulting 123 autosomal SNPs as input to the DEPICT analysis
(Supplementary Material, Table S9). The 123 SNPs grouped into
109 independent loci (using linkage disequilibrium r2 > 0.5 and
a maximum physical distance between lead SNPs and locus
boundaries of 1 Mb to define loci). All genomic coordinates were
defined using genome build hg19.
DEPICT overview
The DEPICT tool (Data-driven Expression Prioritized Integration
for Complex Traits) performs gene set enrichment and gene pri-
oritization based on predicted gene functions (25). For 19 987
genes, we computed the likelihood of membership in each of
14 461 pre-defined gene sets (based on similarities across in
large-scale gene expression data) resulting in 14 461 reconsti-
tuted gene sets. The pre-defined gene sets includedmanually cu-
rated pathways from the KEGG (29), REACTOME (30), and Gene
Ontology databases (31); molecular pathways derived from pro-
tein-protein interaction screens from the InWeb database (33);
and phenotypic gene sets derived from mouse gene knock-out
studies from the Mouse Genetics Initiative database (44), which
jointly represent a wide spectrum of biological annotations.
The reconstituted gene sets are used to (1) facilitate systematic
prioritization of the most likely causal gene(s) at a given asso-
ciated locus without limiting the analysis to genes with well-es-
tablished functional annotations, and (2) to assess whether
genes in associated loci enrich for particular gene sets (including
biological pathways). Prior to the analyses, DEPICT constructs
lists of genes at associated loci by mapping genes to loci if they
reside within, or are overlapping with, boundaries defined by
the most distal SNPs in either direction with LD r2 > 0.5 to the
strongest associated SNP at each locus. DEPICTwas run using de-
fault settings, that is using 500 permutations for bias adjustment,
20 replications for false discovery rate estimation, exclusion of
the extended major histocompatibility complex region (chr. 6:
25–35 Mb) and using normalized expression data from 77 840 Af-
fymetrix microarrays for gene set reconstitution (see (45) for de-
tails). For a complete description of DEPICT, please refer to (25).
The code used to run DEPICT and other analysis conducted in
this paper can be downloaded from https://github.com/perslab/
(last accessed January 19, 2016).
Gene set enrichment control analysis
We defined a set of genes with elevated expression in the human
brain using the RNA-seq BrainSpan data (see the BrainSpan De-
velopmental Transcriptome-based expression analyses section
below). To derive a measure of a gene’s expression in the brain,
we computed for each gene the mean of the brain structure-
specific and developmental stage-specific median expression
levels. Next, we sampled 100 sets each comprising around 112
loci (the number of DEPICT schizophrenia loci) by sampling
SNPs upstreamof transcription start sites of geneswithmean ex-
pression levels above the 95th percentile. We then ran DEPICT on
each set of these 100 sets of input loci and summarized these re-
sults by counting how often a significantly enriched gene set
(from the schizophrenia DEPICT analysis) was in observed with
at least the same false discovery rate across the 100 ‘generic
brain’ DEPICT runs and computed empirical P-values. Reconsti-
tuted gene sets were clustered using Affinity Propagation R soft-
ware (46). The script for clustering DEPICT gene set enrichment
results can be found at https://github.com/perslab/DEPICT (last
accessed January 19, 2016).
Reconstitution of additional gene sets potentially
relevant to schizophrenia
From Genebook (http://atgu.mgh.harvard.edu/~spurcell/genebook/
genebook.cgi) we downloaded the ARC, FMRP (originally derived
from 34), NMDAR, rat pre-synapse active zone (originally derived
from 35) and synaptic vesicle (originally derived from 38) gene
sets used in (3,4). In addition we downloaded proteomics-derived
gene lists for pre-synaptic docking complexes (37) and mouse
pre-synapse active zone (36). The number of genes in the original
gene list and the number of genes after mapping to Ensembl gene
identifiers, performing orthology mapping and limiting to genes
in DEPICT can be found in Supplementary Material, Table S5. Sub-
sequently we reconstituted the gene sets using our previously
Figure 2. Genes prioritized for schizophrenia exhibited higher expression during
postnatal development compared to prenatal development. The 62 genes
prioritized in genome-wide significant schizophrenia loci (dashed line) exhibit
higher expression during postnatal stages (early infancy through adulthood)
compared to prenatal stages (early to late prenatal development; fold-change
1.29, one-sided paired t-test P = 0.005) across the different brain structures (gray
lines). These findings contrast previous findings primarily based on exome
sequencing data by Gilman et al. (24) showing higher expression of likely causal
schizophrenia genes during prenatal stages (dotted line). These analyses were
based on log2 transformed BrainSpan Developmental Transcriptome (40) RNA-
Seq gene expression data. Error bars represent standard deviation across brain
structures.
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described approach (25,45). The area under the receiver operating
characteristics curve estimates were high (>0.85; Supplementary
Material, Table S5), indicating that the expression of the genes
in each of these gene sets are strongly co-regulated. Finally, we
ran DEPICT on the reconstituted gene sets.
Filtering of reconstituted gene sets and visualization
To ensure that significantly enriched reconstituted DEPICT gene
sets represented biology indicated by their identifiers (reconsti-
tuted gene sets are referred to by their original gene name), we
omitted reconstituted gene sets, which did not enrich for the
genes in the original gene set. We used a Spearman rank-sum
test to assess whether genes in the original gene set were overre-
presented in the reconstituted gene set and conservatively omit-
ted reconstituted gene sets for which the Spearman rank-sum
P > 3.5 × 10−6 (∼0.05/14 461). Among 143 significantly enriched re-
constituted gene sets 39 were omitted (Supplementary Material,
Table S10) resulting in 104 significant reconstituted gene sets re-
ported in this paper. The Cytoscape tool was used to visualize
gene sets and their discretized overlap (47).
Genotype-Tissue Expression Project-based tissue
enrichment analysis
We downloaded normalized RNA-Seq gene expression data from
the GTEx Project (28) (www.gtexportal.org; release, pilot 01/31/
2013, patch 1; last accessed January 19, 2016). We further pro-
cessed the RNA-Seq data by Winsorizing values larger than 50
reads per kilobase of transcript per million reads mapped
(RPKM) to 50 (as previously done in 4) and transforming all values
to log2(1+RPKM) values. After limiting genes to genes part of DE-
PICT and discarding genes with no variance across all tissues, we
ended upwith 19 414 genes. All prioritized genes were part of the
processed RNA-Seq data. We discarded tissues with less than 10
samples and computed median gene expression levels (19 682
genes) for the remaining 37 tissues (see Supplementary Material,
Table S11 for the number of samples for each tissue). The result-
ing tissue expression data set was used in DEPICT instead of the
microarray-based tissue expression matrix derived from the
37 427 microarray samples used in the standard DEPICT version.
DEPICT was used to test whether genes in the genome-wide sig-
nificant loci were higher expressed in a given tissue than all other
genes covered in the analysis (two-sided t-test).
Schizophrenia exome sequencing study data used to
validate prioritized genes
We used Swedish exome sequencing data (4) to validate genes
prioritized by DEPICT. We downloaded all genes containing at
least one disruptive variants (frameshift, nonsense and essential
splice site variants) in cases and/or controls withminor allele fre-
quency (MAF) <0.1% (8702 genes; download date: May 2, 2014)
from the Genebook database. Next, we mapped gene symbols
to Ensembl identifiers, which left us with 8,684 genes. A total of
150 genes overlapped with the 362 genes in the 109 associated
schizophrenia loci. We also used Bulgarian trio exome sequen-
cing data (3) to validate prioritized genes. We downloaded all
genes with de novo variants (1368 variants in 616 genes) from
the Genebook database (download date: May 2, 2014), discarded
genes with de novo variants that were not replicated in (3) (re-
ferred to as ‘silent’ in the database) and mapped the remaining
gene symbols to Ensembl identifiers, which left us with 613
genes, of which 16 genes overlapped with the 362 in the 109
associated schizophrenia loci. The ORs were calculated as OR =
oddsprioritized/oddsnon-prioritized. For the rare variant benchmark
we defined oddsprioritized = cases’ count of disruptive variants in
prioritized genes/controls’ count of disruptive variants in priori-
tized genes, and oddsnon-prioritized = cases’ count of disruptive var-
iants in non-prioritized genes/controls’ count of disruptive
variants in non-prioritized genes. For the de novo variant bench-
mark we defined oddsprioritized = number of prioritized de novo
variant genes/number of prioritized genes with no de novo var-
iants, and oddsnon-prioritized = number of non-prioritized de novo
variant genes/number of non-prioritized genes with no de novo
variants.
Postsynaptic density proteomics data used to validate
prioritized genes
Genes encoding proteinmembers of the PSD have previously im-
plicated in especially schizophrenia copy number variation stud-
ies (2). To validate genes prioritized by DEPICT, we retrieved
purified human and mouse cortex PSD proteomics data (39)
from the Genes2Cognition database (www.genes2cognition.org/
db/GeneList/L00000059; last accessed January 19, 2016). We
downloaded the ‘consensus’ sets of 748 human genes (see Sup-
plementary Material, Table S12) and 1061 mouse genes (see Sup-
plementary Material, Table S13) encoding proteins identified in
each of three biological replicas in human andmouse proteomics
experiments (download date: October 23, 2013). After mapping
gene symbols to Ensembl identifiers we were left with 745
human PSD genes and 969 mouse PSD genes (of which 21 and
27 overlapped with the 362 genes in the 109 associated schizo-
phrenia loci, respectively; Supplementary Material, Tables S11
and S12). For each benchmark we defined oddsprioritized = number
of prioritized PSD genes/number of prioritized genes non-PSD
genes, and oddsnon-prioritized = number of non-prioritized PSD
genes/number of non-prioritized non-PSD genes.
Brainspan Developmental Transcriptome-based
expression analyses
We downloaded normalized BrainSpan Developmental Tran-
scriptome RNA-Seq data and microarray data (see www.
brainspan.org/static/download.html; download date October 31,
2014; last accessed January 19, 2016). We further processed the
RNA-Seq data as described in (4), that is values larger than 50
RPKM were Winsorized to 50 and transformed to log2(1+RPKM)
values. In total 4,586 genes were affected by Winsorizing (∼2%
of the expression values). No further normalization was applied
to themicroarray normalization. A total of eight prioritized genes
were missing from the RNA-Seq data (Supplementary Material,
Table S14). The developmental stages were defined using the
BrainSpan Developmental Transcriptome technical white
paper, release October 2013 v.5 (http://help.brain-map.org/display/
devhumanbrain/Documentation; last accessed January 19, 2016).
We computed median gene expression levels for all 26 structures
(across all stages; see Supplementary Material, Table S15 for
sample counts) and for all 12 stages (across all structures; see
Supplementary Material, Table S16 for sample counts). To assess
whether prioritized genes were higher expressed in postnatal
compared to prenatal stages, we computed for each prioritized
gene the average expression prenatal and postnatal expression
value and then used a one-sided paired t-test to signify the differ-
ence in means between the two categories (prenatal group
mean = 3.07; postnatal mean = 2.75). Temporal trajectories of
genes identified by Gilman et al. (24) were plotted the same way
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as we plotted the prioritized genes identified by DEPICT, none of
these genes overlappedwith theprioritized genes (Supplementary
Material, Fig. S4).
Negative controls analyses
To ensure that DEPICT did not bias the results toward postnatally
expressed genes (gene expression data is used as part of the
DEPICT gene prioritization framework), we performed 1000 null
GWAS, ran DEPICT gene prioritization on each of them and
recomputed the pre- versus postnatal expression test for each
of them. In addition, DEPICTwasused to prioritize genes for traits
with at least 10 genome-wide significant associations reported in
the GWAS Catalog database (48) (see Supplementary Material,
Figure S5). DEPICT was run with the same settings as described
above.
Supplementary Material
Supplementary Material is available at HMG online.
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